Integral BioSystems to present NanoM-Wafer data at ARVO 2026

By AI, Created 10:53 AM UTC, May 20, 2026, /AGP/ – Integral BioSystems will present new data on its NanoM-Wafer ocular insert platform at the ARVO 2026 meeting in Denver on May 5, 2026. The company says the technology delivered intact proteins and a small-molecule anti-inflammatory drug for seven days in prototype testing, aiming to improve treatment for corneal surface disorders and other eye diseases.

Why it matters: - NanoM-Wafer is designed to extend drug residence time on the eye, which could help address the fast washout and delivery limits that affect traditional eyedrops. - The platform targets corneal surface disorders and other ocular conditions that often require repeated dosing. - The presentation could interest ophthalmic drug developers looking for longer-acting delivery options for both small molecules and biologics.

What happened: - Integral BioSystems will present NanoM-Wafer data at the Association for Research in Vision and Ophthalmology annual meeting in Denver, Colorado, from May 3 to May 7, 2026. - The presentation is scheduled for May 5, 2026, from 1:15 p.m. to 3:00 p.m. - The poster session is listed under Session 341, “Corneal disease and drug delivery.” - The posterboard number is 2968 - 0144. - The abstract title is “Once-Weekly Administration of Medications via NanoM-Wafer™ Platform for Treatment of Corneal Surface Disorders.” - The authors are Kevin Ward, Akshita Bhardwaj, Sagan Stanczak, Ivan Guerrero and Shikha Barman.

The details: - NanoM-Wafer is a next-generation ocular insert platform developed to efficiently deliver medications to the eye. - The company says prototype insert data showed 7-day sustained release of intact proteins across multiple molecular weights. - Prototype data also showed 7-day linear release of an anti-inflammatory small-molecule drug. - The technology is intended to improve effectiveness, reproducibility and comfort compared with earlier ocular inserts. - Traditional eyedrops face limits from rapid tear drainage, solubility constraints and possible instability of active pharmaceutical ingredients in aqueous solutions. - Integral BioSystems says commercial ocular inserts have had irritation and retention problems. - Integral BioSystems is a specialty drug delivery contract research firm focused on formulation and analytical development for small molecules and biologics. - The company’s proprietary technologies include OcuHeal and NanoM-Wafer. - Integral BioSystems says both technologies are patented in 14 global jurisdictions, including Europe, the U.S., Canada, India, China and Japan. - The company says additional Patent Cooperation Treaty applications are pending as the technologies evolve. - The company invited ophthalmic drug developers to contact its business development team at info@integralbiosystems.com.

Between the lines: - The presentation signals that Integral BioSystems is positioning NanoM-Wafer as a longer-acting alternative to eyedrops and a more practical successor to earlier insert designs. - The seven-day release results suggest the platform is being framed around once-weekly dosing, which could reduce treatment burden if the technology holds up in further testing. - The collaboration push indicates the company is seeking development partners, not just conference visibility.

What’s next: - Integral BioSystems will disclose additional details during the ARVO poster presentation on May 5. - The company is likely to use the meeting to seek partner interest in ophthalmic drug development. - Further validation would be needed before the platform could move toward broader clinical or commercial use.

The bottom line: - Integral BioSystems is using ARVO 2026 to showcase NanoM-Wafer as a potential once-weekly eye drug-delivery platform with longer release than standard eyedrops.